Cargando…

Cutaneous Squamous Cell Carcinoma in the Age of Immunotherapy

SIMPLE SUMMARY: Cutaneous squamous cell carcinoma (cSCC) is the second most prevalent skin cancer globally. Immunosuppression raises cSCC incidence rates, while high immunogenicity of the cutaneous tissue enables topical immunotherapy. Intriguingly, expanded applications of programmed death-1 (PD-1)...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishitsuka, Yosuke, Hanaoka, Yuma, Tanemura, Atsushi, Fujimoto, Manabu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7962464/
https://www.ncbi.nlm.nih.gov/pubmed/33800195
http://dx.doi.org/10.3390/cancers13051148
_version_ 1783665475535765504
author Ishitsuka, Yosuke
Hanaoka, Yuma
Tanemura, Atsushi
Fujimoto, Manabu
author_facet Ishitsuka, Yosuke
Hanaoka, Yuma
Tanemura, Atsushi
Fujimoto, Manabu
author_sort Ishitsuka, Yosuke
collection PubMed
description SIMPLE SUMMARY: Cutaneous squamous cell carcinoma (cSCC) is the second most prevalent skin cancer globally. Immunosuppression raises cSCC incidence rates, while high immunogenicity of the cutaneous tissue enables topical immunotherapy. Intriguingly, expanded applications of programmed death-1 (PD-1) blockade therapies have revealed cSCC to be one of the most amenable targets. These clinical observations prompted us to redefine cSCC biology and review current knowledge about cSCC from multiple viewpoints that involve epidemiology, clinicopathology, molecular genetics, molecular immunology, and developmental biology. This synthesis reinforces the following hypothesis: PD-1 blockade effectively restores the immunity specially allowed to exist within the fully cornified squamous epithelium, that is, the epidermis. ABSTRACT: Cutaneous squamous cell carcinoma (cSCC) is the second most prevalent skin cancer globally. Because most cSCC cases are manageable by local excision/radiotherapy and hardly become life-threatening, they are often excluded from cancer registries in most countries. Compared with cutaneous melanoma that originates from the melanin-producing, neural crest-derived epidermal resident, keratinocyte (KC)-derived cancers are influenced by the immune system with regards to their pathogenetic behaviour. Congenital or acquired immunosurveillance impairments compromise tumoricidal activity and raises cSCC incidence rates. Intriguingly, expanded applications of programmed death-1 (PD-1) blockade therapies have revealed cSCC to be one of the most amenable targets, particularly when compared with the mucosal counterparts arisen in the esophagus or the cervix. The clinical observation reminds us that cutaneous tissue has a peculiarly high immunogenicity that can evoke tumoricidal recall responses topically. Here we attempt to redefine cSCC biology and review current knowledge about cSCC from multiple viewpoints that involve epidemiology, clinicopathology, molecular genetics, molecular immunology, and developmental biology. This synthesis not only underscores the primal importance of the immune system, rather than just a mere accumulation of ultraviolet-induced mutations but also reinforces the following hypothesis: PD-1 blockade effectively restores the immunity specially allowed to exist within the fully cornified squamous epithelium, that is, the epidermis.
format Online
Article
Text
id pubmed-7962464
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79624642021-03-17 Cutaneous Squamous Cell Carcinoma in the Age of Immunotherapy Ishitsuka, Yosuke Hanaoka, Yuma Tanemura, Atsushi Fujimoto, Manabu Cancers (Basel) Review SIMPLE SUMMARY: Cutaneous squamous cell carcinoma (cSCC) is the second most prevalent skin cancer globally. Immunosuppression raises cSCC incidence rates, while high immunogenicity of the cutaneous tissue enables topical immunotherapy. Intriguingly, expanded applications of programmed death-1 (PD-1) blockade therapies have revealed cSCC to be one of the most amenable targets. These clinical observations prompted us to redefine cSCC biology and review current knowledge about cSCC from multiple viewpoints that involve epidemiology, clinicopathology, molecular genetics, molecular immunology, and developmental biology. This synthesis reinforces the following hypothesis: PD-1 blockade effectively restores the immunity specially allowed to exist within the fully cornified squamous epithelium, that is, the epidermis. ABSTRACT: Cutaneous squamous cell carcinoma (cSCC) is the second most prevalent skin cancer globally. Because most cSCC cases are manageable by local excision/radiotherapy and hardly become life-threatening, they are often excluded from cancer registries in most countries. Compared with cutaneous melanoma that originates from the melanin-producing, neural crest-derived epidermal resident, keratinocyte (KC)-derived cancers are influenced by the immune system with regards to their pathogenetic behaviour. Congenital or acquired immunosurveillance impairments compromise tumoricidal activity and raises cSCC incidence rates. Intriguingly, expanded applications of programmed death-1 (PD-1) blockade therapies have revealed cSCC to be one of the most amenable targets, particularly when compared with the mucosal counterparts arisen in the esophagus or the cervix. The clinical observation reminds us that cutaneous tissue has a peculiarly high immunogenicity that can evoke tumoricidal recall responses topically. Here we attempt to redefine cSCC biology and review current knowledge about cSCC from multiple viewpoints that involve epidemiology, clinicopathology, molecular genetics, molecular immunology, and developmental biology. This synthesis not only underscores the primal importance of the immune system, rather than just a mere accumulation of ultraviolet-induced mutations but also reinforces the following hypothesis: PD-1 blockade effectively restores the immunity specially allowed to exist within the fully cornified squamous epithelium, that is, the epidermis. MDPI 2021-03-08 /pmc/articles/PMC7962464/ /pubmed/33800195 http://dx.doi.org/10.3390/cancers13051148 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Ishitsuka, Yosuke
Hanaoka, Yuma
Tanemura, Atsushi
Fujimoto, Manabu
Cutaneous Squamous Cell Carcinoma in the Age of Immunotherapy
title Cutaneous Squamous Cell Carcinoma in the Age of Immunotherapy
title_full Cutaneous Squamous Cell Carcinoma in the Age of Immunotherapy
title_fullStr Cutaneous Squamous Cell Carcinoma in the Age of Immunotherapy
title_full_unstemmed Cutaneous Squamous Cell Carcinoma in the Age of Immunotherapy
title_short Cutaneous Squamous Cell Carcinoma in the Age of Immunotherapy
title_sort cutaneous squamous cell carcinoma in the age of immunotherapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7962464/
https://www.ncbi.nlm.nih.gov/pubmed/33800195
http://dx.doi.org/10.3390/cancers13051148
work_keys_str_mv AT ishitsukayosuke cutaneoussquamouscellcarcinomaintheageofimmunotherapy
AT hanaokayuma cutaneoussquamouscellcarcinomaintheageofimmunotherapy
AT tanemuraatsushi cutaneoussquamouscellcarcinomaintheageofimmunotherapy
AT fujimotomanabu cutaneoussquamouscellcarcinomaintheageofimmunotherapy